Our Pricing

Buy Wegovy Online UK: Private Prescription Without NHS Wait

Published on: June 03, 2026

When you buy Wegovy online UK private prescription services, you can access this clinically proven weight loss treatment without the months-long NHS waiting lists. At Cured Pharmacy, our UK-registered prescribers assess your suitability through a free online consultation, and if approved, your genuine Wegovy (semaglutide) pens are dispensed from our GPhC-registered pharmacy from £79.00 with discreet next-day delivery across the UK.

Why Choose Private Wegovy Prescription Over NHS?

NHS access to Wegovy remains severely restricted due to supply constraints and strict eligibility criteria. Most patients face waiting lists exceeding 12 months, and many CCGs have suspended new referrals entirely [1]. Private prescription services through registered UK pharmacies like Cured Pharmacy offer immediate access, subject to clinical approval by our prescribers.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees every prescription dispensed, ensuring you receive genuine UK-licensed Wegovy pens manufactured by Novo Nordisk. Unlike unregulated online sellers, we operate under full GPhC supervision (registration 9012511) with transparent pricing displayed before your consultation begins.

The private route also provides continuity of care. Your prescriber monitors your progress through follow-up consultations, adjusts dosing as clinically appropriate, and ensures you're achieving optimal results whilst managing any side effects effectively.

How Wegovy Works: The Science Behind Semaglutide

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1. This medication works through three complementary mechanisms: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves insulin sensitivity [2].

In the landmark STEP 1 trial, participants taking the full 2.4mg weekly dose achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [2]. Approximately 50% of participants lost at least 15% of their starting weight, and one-third lost 20% or more — outcomes rarely seen with lifestyle interventions alone.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen. You start at 0.25mg weekly for the first month, then gradually escalate through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg, typically by week 17 [3]. This titration schedule minimises gastrointestinal side effects whilst your body adjusts to the medication.

Who Can Take Wegovy?

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. Your prescriber will calculate your BMI during consultation and assess your medical history for contraindications.

Wegovy is not suitable during pregnancy or breastfeeding, or if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Patients with severe gastrointestinal disease, diabetic retinopathy, or renal impairment require careful clinical assessment before starting treatment.

Wegovy vs Mounjaro vs Saxenda: Choosing Your Treatment

All three medications are injectable GLP-1 treatments licensed by the MHRA for weight management, but they differ in mechanism, dosing frequency, and clinical outcomes. Wegovy (semaglutide) is a pure GLP-1 agonist given once weekly, whilst Saxenda (liraglutide) is an older GLP-1 agonist requiring daily injections.

Mounjaro (tirzepatide) is the newest option and the only dual GIP/GLP-1 receptor agonist available. In head-to-head trials, tirzepatide produced greater weight loss than semaglutide — the SURPASS-2 trial showed 15.7% average weight reduction with tirzepatide 15mg versus 6.7% with semaglutide 1mg over 40 weeks [4]. However, Mounjaro typically costs more and may not be necessary for all patients.

Your prescriber will recommend the most appropriate treatment based on your weight loss goals, budget, tolerance for injection frequency, and any coexisting conditions like type 2 diabetes. Many patients achieve excellent results with Wegovy, particularly when combined with dietary modifications and increased physical activity.

What to Expect: Wegovy Side Effects and Management

The most common side effects of Wegovy are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [3]. These symptoms typically emerge during dose escalation and improve within 4-8 weeks as your body adapts. Approximately 5-10% of trial participants discontinued treatment due to gastrointestinal intolerance.

To minimise side effects, eat smaller, more frequent meals rather than large portions, avoid high-fat and spicy foods, and stay well hydrated. If nausea persists, your prescriber may slow the dose escalation or recommend anti-nausea medication. Never increase your dose faster than the prescribed schedule.

Rare but serious adverse effects include pancreatitis (severe abdominal pain radiating to the back), gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications. Contact your prescriber immediately if you experience persistent severe abdominal pain, visual changes, or signs of an allergic reaction such as facial swelling or difficulty breathing.

Long-Term Safety Profile

Semaglutide has been used for type 2 diabetes management since 2017 (as Ozempic) and has accumulated extensive real-world safety data. The STEP trials followed participants for up to 68 weeks, and cardiovascular outcome studies in diabetic populations showed no increased risk of major adverse cardiac events [5].

Weight regain is common if Wegovy is discontinued, with most patients regaining approximately two-thirds of lost weight within one year of stopping treatment [6]. This reflects the chronic nature of obesity and suggests long-term or maintenance therapy may be necessary for sustained results, subject to ongoing prescriber review.

How to Buy Wegovy Online UK Through Cured Pharmacy

Start by completing our free online medical consultation, which takes under three minutes. You'll answer questions about your weight history, current medications, medical conditions, and weight loss goals. Our UK-registered prescribers review every consultation individually — there are no automatic approvals.

If Wegovy is clinically appropriate for you, your prescription is issued electronically and sent to our dispensing team. We only supply genuine UK-licensed Wegovy pens sourced directly from licensed wholesalers, never grey-market imports. Your medication is dispatched in 100% discreet packaging via next-day tracked courier, with no external branding or pharmacy labels visible.

You'll receive follow-up consultation reminders at 4, 8, and 12 weeks to monitor your progress and adjust treatment as needed. Our clinical team is available by phone during business hours if you have questions about side effects, injection technique, or dose escalation. All ongoing prescriptions require periodic review to ensure continued safety and efficacy.

Wegovy Cost UK: Transparent Pricing Guaranteed

At Cured Pharmacy, Wegovy pricing starts from £79.00 depending on your prescribed dose and treatment duration. Unlike some providers who hide costs until after consultation, we display all prices upfront on our website so you can make an informed decision before starting your assessment.

Each Wegovy pen contains four weekly doses at the same strength, meaning you'll need one pen per month once you reach your maintenance dose. The total monthly cost includes the medication, prescriber review, and delivery — there are no hidden consultation fees or subscription charges. We also offer percentage savings on multi-month supplies when purchased together.

We guarantee the lowest prices for genuine UK-licensed weight loss treatments. If you find a lower price at another GPhC-registered UK pharmacy for the same medication and dose, we'll match it. Beware of suspiciously cheap offers from unregulated websites — counterfeit semaglutide pens containing incorrect doses or no active ingredient have been seized by the MHRA [7].

Payment and Delivery Options

We accept all major credit and debit cards through secure encrypted payment processing. Your medication is dispatched within 24 hours of prescription approval via Royal Mail Tracked 24 or DPD next-day courier, depending on your location and order size.

All parcels arrive in plain packaging with no external indication of contents or sender. If you're not home for delivery, the courier will leave a 'while you were out' card, and you can arrange redelivery or collection from your local depot. We ship to all UK addresses including Northern Ireland, Scottish Highlands, and offshore islands, though delivery times may be slightly longer for remote locations.

Scientific References

1. NHS England. (2023). Update on GLP-1 receptor agonist supply constraints. NHS England. https://www.england.nhs.uk/long-read/update-on-glp-1-receptor-agonist-supply-constraints/ [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen – Summary of Product Characteristics. Novo Nordisk Limited. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
5. Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141 [accessed 13 August 2026]
6. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
7. Medicines and Healthcare products Regulatory Agency. (2024). Falsified Ozempic (semaglutide) pre-filled pens identified in the UK. GOV.UK. https://www.gov.uk/drug-safety-update/falsified-ozempic-semaglutide-pre-filled-pens-identified-in-the-uk [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.